Clinical Trials
25 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT00544414 2025-02-19
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
City of Hope Medical Center
Phase 2 Completed
NCT03840421 2025-01-13
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT01172470 2023-11-29
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients
University of Chicago
Phase 2 Completed
NCT00079079 2023-08-04
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
Canadian Cancer Trials Group
Phase 2 Completed
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT00997906 2022-09-29
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC
National Cancer Centre, Singapore
Phase 2/3 Unknown
NCT00394147 2022-08-05
Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT00248560 2019-03-05
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00509665 2018-07-12
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00620295 2017-11-29
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00256295 2017-02-01
Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer
University of California, Irvine
Phase 2 Terminated
NCT00003744 2017-01-19
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01325558 2016-07-15
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
Phase 1 Completed
NCT00176241 2015-06-08
Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer
University of Kentucky
Phase 1 Terminated
NCT00589667 2014-04-02
A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003182 2013-12-04
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00004097 2013-09-20
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00014456 2013-08-28
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00003264 2013-04-17
Cisplatin Plus Gemcitabine in Treating Patients With Advanced Squamous Cell Head and Neck Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00100789 2012-10-01
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00017498 2012-09-24
Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00690872 2009-06-29
Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown